A strong ending of an eventful year
Press release (MAR) Malmö, February 18, 2021 Acarix AB (publ) publishes Year-End Report 2020 A strong ending of an eventful yea...
Acarix announces the last patient included in Dan-NICAD II study
Press release Malmö, Sweden December 9, 2020 Acarix announces the last patient included in Dan-NICAD II study After the inclusi...
FDA identifies exclusive code for the CADScor®
Press release (MAR)Malmö, Sweden, November 26, 2020 FDA identifies exclusive code for the CADScor® After yesterday’s a...
Acarix receives US market approval for the CADScor® System
Press release (MAR)Malmö, Sweden November 25, 2020 Acarix receives US market approval for the CADScor® System Acarix AB (pu...
Positive results from Acarix study presented at ISPOR, a leading health economics conference
Press releaseMalmö, Sweden November 18, 2020 Positive results from Acarix study presented at ISPOR, a leading health economics co...
Correction: Interim report 2020-01-01 to 2020-09-30
Press release (MAR) Malmö, November 12, 2020 Correction: Interim report 2020-01-01 to 2020-09-30 In the interim report that Ac...
A Successful Rights Issue with Focus on Sales!
Press release (MAR) Malmö, November 12, 2020 Acarix AB (publ) publishes Interim Report, January – September 2020 A Success...
Acarix changes Certified Advisor to Redeye
Press release Malmö, Sweden October 15, 2020 Acarix changes Certified Advisor to Redeye Acarix AB (publ) announces t...
Acarix carries out a directed issue of shares to guarantors in conjunction with the oversubscribed rights issue
Press release Malmö, Sweden September 29, 2020 Acarix carries out a directed issue of shares to guarantors in conjunction with th...
Last day of trading in paid subscribed shares (Sw. BTA)
Press release Malmö, Sweden September 28, 2020 Last day of trading in paid subscribed shares (Sw. BTA) Last day of trading in su...
Acarix announce final outcome in oversubscribed rights issue
Press release Malmö, Sweden September 11, 2020 Acarix announce final outcome in oversubscribed rights issue Acarix AB ("Acarix"...